[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-circulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-circulation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100642949","a-single-center-randomized-double-blind-placebo-controlled-intervention-clinical-trial-to-evaluate-the-efficacy-and-safety-of-koreaginseng-f-max-on-blood-circulation-improvement-in-adults-with-poor-peripheral-blood-flow-100642949",false,"NCT07643532","A Single-center, Randomized, Double-blind, Placebo-controlled, Intervention Clinical Trial to Evaluate the Efficacy and Safety of \"KoreaGinseng F Max\" on Blood Circulation Improvement in Adults With Poor Peripheral Blood Flow","Inclusion Criteria:\n\n* Men or women aged 20 to under 65 years\n* Platelet aggregation response above 55% (satisfied for both collagen and ADP)\n* Provides voluntary written informed consent to participate\n\nExclusion Criteria:\n\n* History of hypersensitivity or allergy to ginseng-containing products that may affect the results\n* Surgery under general anesthesia within 12 weeks before participation\n* Use of contraindicated products such as red ginseng or omega-3 fatty acids within 2 weeks before screening\n* Use of antiplatelet drugs such as aspirin within 2 weeks before screening (subjects on prophylactic aspirin \\\u003C100 mg with unchanged dose\u002Fmethod may participate)\n* Uncontrolled hypertension not managed by medication (systolic BP \\>160 mmHg or diastolic BP \\>97 mmHg)\n* Currently using study-indicated medications such as those for dyslipidemia or diabetes\n* On drug treatment with a history of peripheral atherosclerosis and coronary artery disease (peripheral vascular disease, abdominal aortic aneurysm, carotid artery disease)\n* Coronary artery bypass surgery, vascular anastomosis, pacemaker use, myocardial infarction, heart failure, arrhythmia, or other cardiac disease within 6 months\n* Infectious inflammatory disease, systemic infection, immune-resistance-related disease, or leukemia (blood cancer)\n* Irritable bowel syndrome, gastrointestinal resection surgery, or GI-related disease such as Crohn's disease\n* History of cerebral ischemia or cerebral hemorrhage such as cerebral infarction or stroke due to atherosclerosis\n* Concurrent symptoms of myocardial infarction, atherosclerosis, or congestive heart failure\n* Clinically significant liver dysfunction (ALT or AST ≥2.5x the upper limit of normal)\n* Clinically significant renal dysfunction (serum creatinine \\>2.0 mg\u002FdL)\n* TSH outside 0.27-5.07 microIU\u002FmL or thyroid disease\n* History of, or current treatment for, psychiatric\u002Fneurological disorders including schizophrenia, depression, or drug addiction\n* History of malignant tumor within 5 years before screening\n* Pregnant or breastfeeding women, women of childbearing potential not using medically reliable contraception, or women within 6 months postpartum\n* Alcohol consumption within the last 3 days (men 30 g\u002Fday, women 20 g\u002Fday)\n* Participation in another clinical trial within 4 weeks before participation\n* Subjects judged unsuitable by the investigator or other physicians",true,"ALL","20 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a white ginseng extract (KoreaGinseng F Max) for improving blood circulation in adults with poor peripheral blood flow.\n\nA total of 100 adults aged 20 to under 65 years with platelet aggregation above 55% will be enrolled and randomly assigned in a 1:1 ratio to receive either the white ginseng extract or a matching placebo for 8 weeks. Each participant takes 3 tablets after breakfast and 3 tablets after dinner (6 tablets per day).\n\nThe main goal is to measure the change in ADP-induced platelet aggregation from baseline (Visit 2) to the end of treatment (Visit 4, Week 8). The study also assesses effects on coagulation measures, blood lipids, serotonin, blood pressure, white blood cell count, and overall safety.",[27,28,29],"Blood Circulation","Peripheral Blood Flow","Platelet Aggregation",[31,32,33,34,35,36,37],"White ginseng extract","KoreaGinseng F Max","Platelet aggregation","Blood circulation","Antiplatelet","Dietary supplement","Functional food","NOT_YET_RECRUITING","2026-06-08",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":21},"2026-06-10",{"date":46,"type":21},"2028-06-10",{"name":48,"class":49},"Haiphong University of Medicine and Pharmacy","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":15,"sex":16,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100627242","electric-stimulation-home-usecgm-mepc2401-for-improving-blood-circulation-100627242","NCT07446088","Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation","A Single-center, Open-label, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of a Statics Electricity Generator for Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation","Inclusion Criteria:\n\n* Adults aged between 19 and 65 years\n* Individuals with a BMI of 30.0 kg\u002Fm² or less\n* Individuals without abnormal findings on hematology tests (CBC)\n\nExclusion Criteria:\n\n* Patients with uncontrolled hypertension despite medication (defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg measured at rest)\n* Patients with medical conditions requiring the use of assistive devices (e.g., pacemaker, artificial joint, stent, prosthesis, etc.)\n* Patients with seizure disorders or a history of loss of consciousness (e.g., epilepsy, acute febrile convulsions such as those associated with severe fever, etc.), or those at high risk of electric shock due to such conditions\n* Patients with ventricular arrhythmias (e.g., ventricular tachycardia, history of coronary artery bypass surgery, etc.) and patients with neurological disorders (e.g., diabetic neuropathy, etc.)","19 Years",{"count":60,"type":21},40,[24],"This study is a single-center, open-label, exploratory clinical trial to evaluate the safety and efficacy of a statics electricity generator for improving blood circulation.",[64,27],"Improving Blood Circulation",[66],"blood circulation","RECRUITING","2026-02-25",{"date":70,"type":42},"2026-03-03",{"date":72,"type":42},"2025-12-01",{"date":74,"type":21},"2026-06-30",{"name":76,"class":77},"Ceragem Clinical Inc.","INDUSTRY",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":50},"100583604","phase-4-effect-of-blood-flow-by-botulinum-toxin-injection-for-severe-peripheral-artery-occlusive-disease-100583604","NCT06878482","Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease","Effect of Increasing Blood Flow by Botulinum Toxin Local Injection for Severe Peripheral Artery Occlusive Disease: Preliminary Report","Inclusion Criteria:\n\n1. Age ≥ 20 years old\n2. Patients who have a lower extremity wound among those who have been diagnosed with moderate or severe lower extremity ischemia\n3. Patients who are unable to perform additional procedures (angioplasty, etc.) by performing peripheral vascular examination and CT angiography\n4. Wound size ≥ 1x1cm2 to ≤ 3x3cm2\n5. Patients who can follow the clinical trial procedure well and abide by the visit schedule\n6. Written informed consent to participate in the study after having fully understood the contents of the protocol and restrictions.\n\nExclusion Criteria:\n\n1. Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy\n2. Within 4 weeks before screening, aminoglycoside antibiotics, curare-like agents, or drugs that inhibit neuromuscular function (muscle relaxants, anticholinergics, benzodiazepines, benzamides, tetracyclines, Rinco Those who have taken mycin antibiotics, etc.)\n3. Those taking aspirin, NSAIDs or anticoagulants within 7 days before screening\n4. Those who have received botulinum toxin preparations within 3 months before screening\n5. Angiography or CT angiography If one or more of the three major blood vessels in the lower extremity are open\n6. Cases in which blood flow to the lower extremities can be preserved by performing balloon angioplasty even if all three major blood vessels in the lower extremity are blocked\n7. Those who are currently taking steroids or immunosuppressants that affect wounds, or those who have taken them within one month of screening\n8. Those who have applied injection drugs or wound coverings that help improve wounds within 1 week of screening\n9. Women who are pregnant, lactating, planning to become pregnant during the clinical period, or women of childbearing age who are not using available contraceptive methods (women of childbearing age must be negative in the pregnancy test prior to injection).\n10. Those who are allergic or sensitive to botulinum toxin\n11. Those who have participated in another clinical trial within 30 days before screening or those who have not passed the half-life of the investigational product of the clinical trial that they participated in, whichever is longer.\n12. Those who are not suitable for this clinical trial under the judgment of other investigators",{"count":86,"type":21},15,[88],"PHASE4","The purpose of this study is to investigate the effect of subcutaneous injection of botulinum toxin A on wound healing caused by lower extremity ischemia.",[91,92,93,27],"Chronic Ulcer of Lower Extremity","Wound","Botulinum Toxins, Type A",[93,92,91,27],"2025-03-11",{"date":97,"type":42},"2025-03-17",{"date":99,"type":42},"2023-04-17",{"date":101,"type":21},"2026-03-31",{"name":103,"class":49},"Yonsei University"]